Companies in #CNS Drug Development

DemeRx is a clinical-stage biopharmaceutical company developing ibogaine-derived therapeutics for substance use disorders and other CNS conditions. Its lead candidate DMX-1001 is an oral noribogaine formulation designed to retain the anti-addiction properties of ibogaine while improving cardiac safety and pharmacokinetic control. The company is launching the first U.S. clinical trial of an ibogaine-derived candidate, advancing a long-controversial psychedelic mechanism into modern clinical development.

Neumora Therapeutics is a clinical-stage neuroscience company developing precision medicines for brain diseases with high unmet need. Its lead asset NMRA-140 (navacaprant) is a kappa opioid receptor antagonist studied in major depressive disorder, and the company has additional programs in schizophrenia and other CNS indications. Following two Phase 3 failures in mid-2026, Neumora announced a 35% workforce reduction and is discontinuing development of its lead depression asset.